PSPamela A. Szweda

Pamela A. Szweda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pamela A. Szweda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Luke I. Szweda

    Department of Internal Medicine (Cardiology) (D.D., S.D.G., A.A., H.I.M., N.J., C.I.I., A.F., V.G.-M., N.N., L.M.-R., D.D.Z., F.O.-S., G.C., F.W., B.A.R., L.I.S., S.L., T.G.G., J.A.H.), UT Southwestern Medical Center, Dallas, TX

    3 shared publications
  • Francisco Altamirano

    Department of Cardiovascular Sciences Houston Methodist Research Institute Houston Methodist Hospital Houston Texas USA

    2 shared publications
  • Gabriele Giacomo Schiattarella

    Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Deutsches Herzzentrum der Charité (DHZC), Charité-Universitätsmedizin Berlin, Germany (G.G.S.).

    2 shared publications
  • Joseph A. Hill

    Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX, USA

    2 shared publications
  • Nan Jiang

    Internal Medicine (Cardiology) (D.T., G.G.S., N.J., F.A., P.A.S., A.E., H.Y., L.I.S., S.L., T.G.G., J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX

    2 shared publications
  • Sergio Lavandero

    Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Quimicas y Farmaceuticas & Facultad de Medicina, Universidad de Chile, Santiago, 8380494, Chile; Núcleo de Biología y Genética (NiBG), Instituto de Ciencias Biomedicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, 8330351, Chile; Cardiology Division, Harry S. Moss Heart Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9047, USA

    2 shared publications

Latest Publications

  • Top Cited Papers

    NAD + Repletion Reverses Heart Failure With Preserved Ejection Fraction

    by Dan Tong, Gabriele G. Schiattarella, Nan Jiang, Francisco Altamirano, Pamela A. Szweda, Abdallah Elnwasany, Dong I. Lee, Heesoo Yoo, David A. Kass, Luke I. Szweda, et al.

    Rationale: Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. We recently demonstrated in mice that a combination of metabolic and hypertensive stress recapitulates key features of human HFpEF. Objective: Using this novel preclinical HFpEF model, we set out to define and manipulate metabolic dysregulations occurring in HFpEF myocardium. Methods and Results: We observed impairment in mitochondrial fatty acid oxidation associated with hyperacetylation of key enzymes in the pathway. Downregulation of sirtuin 3 and deficiency of NAD + secondary to an impaired NAD + salvage pathway contribute to this mitochondrial protein hyperacetylation. Impaired expression of genes involved in NAD + biosynthesis was confirmed in cardiac tissue from patients with HFpEF. Supplementing HFpEF mice with nicotinamide riboside or a direct activator of NAD + biosynthesis led to improvement in mitochondrial function and amelioration of the HFpEF phenotype. Conclusions: Collectively, these studies demonstrate that HFpEF is associated with myocardial mitochondrial dysfunction and unveil NAD + repletion as a promising therapeutic approach in the syndrome.


  • Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function

    by Soo Young Kim, Xin Zhang, Gabriele G. Schiattarella, Francisco Altamirano, Thais A.R. Ramos, Kristin M. French, Nan Jiang, Pamela A. Szweda, Bret M. Evers, Herman I. May, et al.

    Background: BET (bromodomain and extraterminal) epigenetic reader proteins, in particular BRD4 (bromodomain-containing protein 4), have emerged as potential therapeutic targets in a number of pathological conditions, including cancer and cardiovascular disease. Small-molecule BET protein inhibitors such as JQ1 have demonstrated efficacy in reversing cardiac hypertrophy and heart failure in preclinical models. Yet, genetic studies elucidating the biology of BET proteins in the heart have not been conducted to validate pharmacological findings and to unveil potential pharmacological side effects. Methods: By engineering a cardiomyocyte-specific BRD4 knockout mouse, we investigated the role of BRD4 in cardiac pathophysiology. We performed functional, transcriptomic, and mitochondrial analyses to evaluate BRD4 function in developing and mature hearts. Results: Unlike pharmacological inhibition, loss of BRD4 protein triggered progressive declines in myocardial function, culminating in dilated cardiomyopathy. Transcriptome analysis of BRD4 knockout mouse heart tissue identified early and specific disruption of genes essential to mitochondrial energy production and homeostasis. Functional analysis of isolated mitochondria from these hearts confirmed that BRD4 ablation triggered significant changes in mitochondrial electron transport chain protein expression and activity. Computational analysis identified candidate transcription factors participating in the BRD4-regulated transcriptome. In particular, estrogen-related receptor α, a key nuclear receptor in metabolic gene regulation, was enriched in promoters of BRD4-regulated mitochondrial genes. Conclusions: In aggregate, we describe a previously unrecognized role for BRD4 in regulating cardiomyocyte mitochondrial homeostasis, observing that its function is indispensable to the maintenance of normal cardiac function.


  • Cardiac Reperfusion Injury: Aging, Lipid Peroxidation, and Mitochondrial Function

    by Luke I. Szweda, David T. Lucas, Kenneth M. Humphries, Pamela A. Szweda